202P Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: A SONABRE study

N. Ding, S.M.E. Geurts, J. Tol, B.E.P.J. Vriens, K.N.A. Aaldering, E. Boon, M.W. Dercksen, F. Van den Berkmortel, M.J.A.E. Pepels, N.A.J.B. Peters, J.B. Heijns, L.V.D. Winkel, A.J.O. de Fallois, V.C.G. Tjan-Heijnen,M. De Boer

ESMO Open（2024）

引用 0|浏览0